Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 3
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?
van Ee TJ, Van Acker HH, van Oorschot TG, Van Tendeloo VF, Smits EL, Bakdash G, Schreibelt G, de Vries IJM. van Ee TJ, et al. Among authors: van oorschot tg. Vaccines (Basel). 2018 Sep 19;6(3):65. doi: 10.3390/vaccines6030065. Vaccines (Basel). 2018. PMID: 30235890 Free PMC article. Review.
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.
Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Mus RD, Croockewit SA, Jacobs JF, Schuler G, Neyns B, Austyn JM, Punt CJ, Schreibelt G, de Vries IJ. Bol KF, et al. Oncoimmunology. 2015 Apr 1;4(8):e1019197. doi: 10.1080/2162402X.2015.1019197. eCollection 2015 Aug. Oncoimmunology. 2015. PMID: 26405571 Free PMC article.
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Tel J, Winkels G, Petry K, Blokx WA, van Rossum MM, Welzen ME, Mus RD, Croockewit SA, Koornstra RH, Jacobs JF, Kelderman S, Blank CU, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ. Schreibelt G, et al. Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28. Clin Cancer Res. 2016. PMID: 26712687 Clinical Trial.
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ. Boudewijns S, et al. Oncoimmunology. 2016 May 31;5(7):e1191732. doi: 10.1080/2162402X.2016.1191732. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622047 Free PMC article.
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, Blokx WA, Oyen WJ, Boerman OC, Mus RD, van Rossum MM, van der Graaf CA, Punt CJ, Adema GJ, Figdor CG, de Vries IJ, Schreibelt G. Bol KF, et al. Cancer Immunol Immunother. 2016 Mar;65(3):327-39. doi: 10.1007/s00262-016-1796-7. Epub 2016 Feb 10. Cancer Immunol Immunother. 2016. PMID: 26861670 Free PMC article.